Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-15 4:05 pm Purchase | 2025-05-08 | 13G | Relay Therapeutics, Inc. RLAY | Commodore Capital LP | 10,000,000 5.800% | 10,000,000 (New Position) | Filing History |
| 2025-05-14 4:05 pm Purchase | 2025-05-07 | 13G | Tyra Biosciences, Inc. TYRA | Commodore Capital LP | 2,750,000 5.200% | 2,750,000 (New Position) | Filing History |
| 2025-04-11 5:15 pm Purchase | 2025-04-04 | 13G | Viridian Therapeutics, Inc. VRDN | Commodore Capital LP | 4,300,000 5.300% | 2,375,926 (+123.48%) | Filing History |
| 2025-04-10 4:05 pm Purchase | 2025-04-03 | 13G | Celldex Therapeutics, Inc. CLDX | Commodore Capital LP | 3,350,000 5.000% | 3,350,000 (New Position) | Filing History |
| 2025-02-25 4:05 pm Purchase | 2025-02-18 | 13G | Solid Biosciences Inc. SLDB | Commodore Capital LP | 5,825,000 7.600% | 5,825,000 (New Position) | Filing History |
| 2025-02-14 5:20 pm Sale | 2024-12-31 | 13G | Nkarta, Inc. NKTX | Commodore Capital LP | 351,848 0.500% | -4,310,225 (-92.45%) | Filing History |
| 2025-02-14 5:14 pm Sale | 2024-12-31 | 13G | Celcuity Inc. CELC | Commodore Capital LP | 1,095,650 2.900% | -1,122,332 (-50.60%) | Filing History |
| 2025-02-14 4:05 pm Purchase | 2024-12-31 | 13G | Nkarta, Inc. NKTX | Commodore Capital LP | 351,848 0.500% | 351,848 (New Position) | Filing History |
| 2025-02-14 4:05 pm Purchase | 2024-12-31 | 13G | Celcuity Inc. CELC | Commodore Capital LP | 1,095,650 2.900% | 1,095,650 (New Position) | Filing History |
| 2025-02-14 4:05 pm Purchase | 2024-12-31 | 13G | Bright Minds Biosciences Inc. DRUG | Commodore Capital LP | 500,000 7.200% | 100,000 (+25.00%) | Filing History |
| 2025-02-14 4:05 pm Purchase | 2025-02-07 | 13G | Nurix Therapeutics, Inc. NRIX | Commodore Capital LP | 3,850,000 5.100% | 3,850,000 (New Position) | Filing History |
| 2024-12-17 4:06 pm Purchase | 2024-12-10 | 13G | Cardiff Oncology, Inc. CRDF | Commodore Capital LP | 5,384,616 8.100% | 5,384,616 (New Position) | Filing History |
| 2024-12-16 9:51 pm Purchase | 2024-12-09 | 13G | Merus N.V. MRUS | Commodore Capital LP | 3,750,000 5.500% | 400,000 (+11.94%) | Filing History |
| 2024-12-11 4:05 pm Purchase | 2024-12-04 | 13G | Neurogene Inc. NGNE | Commodore Capital LP | 800,000 5.400% | 800,000 (New Position) | Filing History |
| 2024-11-14 4:10 pm Sale | 2024-09-30 | 13G | Vera Therapeutics, Inc. VERA | Commodore Capital LP | 2,475,000 4.500% | -1,425,000 (-36.54%) | Filing History |
| 2024-11-14 4:05 pm Sale | 2024-09-30 | 13G | Merus N.V. MRUS | Commodore Capital LP | 3,350,000 4.900% | -1,397,373 (-29.43%) | Filing History |
| 2024-11-14 4:05 pm Purchase | 2024-09-30 | 13G | Enliven Therapeutics, Inc. ELVN | Commodore Capital LP | 4,100,000 8.700% | 1,198,184 (+41.29%) | Filing History |
| 2024-11-14 4:05 pm Sale | 2024-02-29 | 13G | Vera Therapeutics, Inc. VERA | Commodore Capital LP | 3,900,000 7.300% | -1,550,000 (-28.44%) | Filing History |
| 2024-11-14 4:05 pm Sale | 2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC | Commodore Capital LP | 3,410,384 4.800% | -389,616 (-10.25%) | Filing History |
| 2024-11-14 4:05 pm Purchase | 2024-09-30 | 13G | Mind Medicine (MindMed) Inc. MNMD | Commodore Capital LP | 8,176,721 9.900% | 2,343,388 (+40.17%) | Filing History |